NASDAQ: ONC
Beigene Ltd Stock Forecast, Predictions & Price Target

Analyst price target for ONC

Based on 4 analysts offering 12 month price targets for Beigene Ltd

Min Forecast
$235.00+6.23%
Avg Forecast
$270.75+22.39%
Max Forecast
$300.00+35.61%

Should I buy or sell ONC stock?

Based on 4 analysts offering ratings for Beigene Ltd.

Strong Buy
Strong Buy
3 analysts 75%
Buy
1 analysts 25%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their ONC stock forecasts and price targets.

ONC stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-12-03
lockedlocked$00.00+00.00%2024-11-13
lockedlocked$00.00+00.00%2024-10-22Find Out Why
lockedlocked$00.00+00.00%2024-09-18

1 of 1

Forecast return on equity

Is ONC forecast to generate an efficient return?

Company
532.46%
Industry
239.02%
Market
89.49%
ONC's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ONC forecast to generate an efficient return on assets?

Company
313.77%
Industry
35.08%
ONC is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ONC earnings per share forecast

What is ONC's earnings per share in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
-$0.02
Avg 2 year Forecast
$4.55
Avg 3 year Forecast
$11.24

ONC revenue forecast

What is ONC's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$4.8B+45.75%
Avg 2 year Forecast
$5.9B+76.74%
Avg 3 year Forecast
$6.7B+103.14%
ONC's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ONC revenue growth forecast

How is ONC forecast to perform vs Biotechnology companies and vs the US market?

Company
26.85%
Industry
49.9%
Market
11.74%
ONC's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ONC's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ONC vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ONC$221.22$270.75+22.39%Strong Buy
BNTX$114.50$146.83+28.23%Strong Buy
RPRX$32.25$45.50+41.09%Strong Buy
UTHR$353.31$417.56+18.18%Strong Buy
INSM$79.89$94.43+18.20%Strong Buy

Beigene Stock Forecast FAQ

Is Beigene Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: ONC) stock is to Strong Buy ONC stock.

Out of 4 analysts, 3 (75%) are recommending ONC as a Strong Buy, 1 (25%) are recommending ONC as a Buy, 0 (0%) are recommending ONC as a Hold, 0 (0%) are recommending ONC as a Sell, and 0 (0%) are recommending ONC as a Strong Sell.

If you're new to stock investing, here's how to buy Beigene stock.

What is ONC's earnings growth forecast for 2025-2027?

(NASDAQ: ONC) Beigene's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.36%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.55%.

Beigene's earnings in 2025 is -$860,458,000.On average, 6 Wall Street analysts forecast ONC's earnings for 2025 to be -$27,720,686, with the lowest ONC earnings forecast at -$4,878,840,806, and the highest ONC earnings forecast at $2,924,532,415. On average, 4 Wall Street analysts forecast ONC's earnings for 2026 to be $6,306,456,156, with the lowest ONC earnings forecast at $401,949,953, and the highest ONC earnings forecast at $11,240,738,335.

In 2027, ONC is forecast to generate $15,572,095,585 in earnings, with the lowest earnings forecast at $12,377,286,478 and the highest earnings forecast at $18,766,904,693.

What is ONC's revenue growth forecast for 2025-2027?

(NASDAQ: ONC) Beigene's forecast annual revenue growth rate of 26.85% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 49.9%, and while it is forecast to beat the US market's average forecast revenue growth rate of 11.74%.

Beigene's revenue in 2025 is $3,316,826,000.On average, 4 Wall Street analysts forecast ONC's revenue for 2025 to be $6,700,304,738,200, with the lowest ONC revenue forecast at $6,532,934,163,888, and the highest ONC revenue forecast at $6,870,784,187,491. On average, 4 Wall Street analysts forecast ONC's revenue for 2026 to be $8,125,057,926,929, with the lowest ONC revenue forecast at $7,546,263,855,240, and the highest ONC revenue forecast at $8,538,110,014,632.

In 2027, ONC is forecast to generate $9,339,047,964,890 in revenue, with the lowest revenue forecast at $8,592,567,303,065 and the highest revenue forecast at $10,684,384,159,152.

What is ONC's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: ONC) forecast ROA is 313.77%, which is higher than the forecast US Biotechnology industry average of 35.08%.

What is ONC's Price Target?

According to 4 Wall Street analysts that have issued a 1 year ONC price target, the average ONC price target is $270.75, with the highest ONC stock price forecast at $300.00 and the lowest ONC stock price forecast at $235.00.

On average, Wall Street analysts predict that Beigene's share price could reach $270.75 by Dec 3, 2025. The average Beigene stock price prediction forecasts a potential upside of 22.39% from the current ONC share price of $221.22.

What is ONC's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: ONC) Beigene's current Earnings Per Share (EPS) is -$0.64. On average, analysts forecast that ONC's EPS will be -$0.02 for 2025, with the lowest EPS forecast at -$3.52, and the highest EPS forecast at $2.11. On average, analysts forecast that ONC's EPS will be $4.55 for 2026, with the lowest EPS forecast at $0.29, and the highest EPS forecast at $8.11. In 2027, ONC's EPS is forecast to hit $11.24 (min: $8.93, max: $13.54).

What is ONC's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: ONC) forecast ROE is 532.46%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.